| HOME >> BIOLOGY >> TECHNOLOGY |
WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting clotting factor VIIa (Factor Vlla-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). PROLOR's Factor VIIa-CTP is a next-generation investigational therapy currently in advanced preclinical development for the potential treatment of patients with hemophilia.
Currently, factor VIIa therapy is available only as an intravenous (IV) formulation, which can be onerous for patients. The company will present new data at the EAHAD Congress showing that PROLOR's long-acting Factor VIIa-CTP has demonstrated the potential for subcutaneous (SC) administration in addition to standard IV dosing. PROLOR researchers believe that a long-acting factor VIIa therapy that could be administered subcutaneously, using a simple injection, would allow children and adults with hemophilia to easily self-administer factor Vlla at home on a prophylactic basis, significantly improving their quality of life.
Dr. Abraham Havron , CEO of PROLOR, commented, "We have previously presented data in animal models of hemophilia showing that Factor Vlla-CTP demonstrated superiority across key efficacy and safety parameters as compared to current factor VIIa therapy. The potential for SC administration may represent a major competitive advantage for our long-acting Factor Vlla-CTP, and we expect to initiate a Phase II clinical trial in hemophilia patients in late 2013 or early 2014."
The data will be presented from 5:00-8:00pm local time on February 6, 2013 by Dr. Gili Hart , Director of Pre-Clinical Affairs at PROLOR and head of the company's long-acting clotting factors program. The European Association fo
'/>"/>
| SOURCE PROLOR Biotech, Inc. Copyright©2012 PR Newswire. All rights reserved |